ReportResolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy
Section snippets
Patients and samples
Patients with moderate/severe psoriasis who had failed previous systemic therapy were recruited from our dermatology and rheumatology outpatient clinics. The study was approved by our local research and ethics committee and all clinical investigation was conducted according to the principles of the Declaration of Helsinki. After fully informed, written consent, patients underwent a full clinical assessment and skin biopsy before receiving anti-TNF-α therapy. Clinical assessments included
Patient demographics
Sixteen patients (13 male, 3 female) with moderate to severe psoriasis (median PASI 15.8) and previous failure to systemic therapy undergoing infliximab treatment were recruited; 13 had associated PsA. Of the 16 patients, 9 were taking concomitant systemic medication in the form of methotrexate (n = 4), cyclosporine (n = 2), and prednisolone (n = 3). The median age was 44 years (range 22-57), the median duration of psoriasis was 25 years, and PsA was 12.5 years. Fifteen patients completed the
Discussion
In this study a cohort of patients with moderate/severe psoriasis, many with an associated arthritis, who had failed systemic therapy, showed a dramatic clinical response to intravenous infliximab. PASI scores and BSA of psoriasis showed highly significant reductions as early as week 2 with further improvement at week 12. Patients with an associated arthritis also showed significant responses as measured by the joint DAS-28 and the HAQ functional assessment. Although the clinical efficacy of
References (50)
Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment
Dermatol Clin
(1996)- et al.
Tumor necrosis factor
J Am Acad Dermatol
(1991) - et al.
Microcirculation in psoriatic skin
J Invest Dermatol
(1974) - et al.
Ultrastructure of the capillary loops in the dermal papillae of psoriasis
J Invest Dermatol
(1977) - et al.
Active and inactive edges of psoriatic plaques: identification by tracing and investigation by laser–Doppler flowmetry and immunocytochemical techniques
J Invest Dermatol
(1989) - et al.
Human keratinocytes express the three major splice forms of vascular endothelial growth factor
J Invest Dermatol
(1995) - et al.
Endothelial cells in physiology and in the pathophysiology of vascular disorders
Blood
(1998) - et al.
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
Cell
(1996) - et al.
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis
J Invest Dermatol
(2001) - et al.
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial
Lancet
(2000)
Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
J Am Acad Dermatol
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial
Lancet
Cytokine mRNA quantification by real-time PCR
J Immunol Methods
Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology
J Immunol Methods
Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab
J Am Acad Dermatol
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
J Am Acad Dermatol
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
J Am Acad Dermatol
Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
Gastroenterology
Tumor necrosis factor-alpha upregulates angiopoietin-2 in human umbilical vein endothelial cells
Biochem Biophys Res Commun
A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice
Am J Pathol
Recent developments in the understanding of the pathogenesis of psoriasis
Br J Dermatol
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis
Arthritis Rheum
Requirement of vascular integrin alpha v beta 3 for angiogenesis
Science
Altered vascular endothelium integrin expression in psoriasis
Am J Pathol
Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis
Am J Pathol
Cited by (100)
Topical delivery of Anti-VEGF nanomedicines for treating psoriasis
2023, Journal of Drug Delivery Science and TechnologyPathogenesis, multi-omics research, and clinical treatment of psoriasis
2022, Journal of AutoimmunityAnimal models of psoriasis—highlights and drawbacks
2021, Journal of Allergy and Clinical ImmunologyMiR-876-5p suppresses cell proliferation by targeting Angiopoietin-1 in the psoriasis
2018, Biomedicine and PharmacotherapyCitation Excerpt :It was also required for angiogenesis and heart development during embryogenesis [16]. Ang-1 was reported to be high in psoriasis [17]. By sequencing and screening of total micro RNA in patients’ samples, some important human micro RNAs with abnormal expression were detected.
Angiogenesis in Dermatology – Insights of Molecular Mechanisms and Latest Developments
2017, Actas Dermo-SifiliograficasCitation Excerpt :Current treatment strategies already interfere in the complex cytokine network that promotes angiogenesis in psoriasis. Anti-TNF treatment with Infliximab of 16 patients with moderate-severe psoriasis could significantly reduce levels of VEGF, Ang-2, TNF alpha and mRNA expression by PCR of Ang1 and Tie-2 receptor in cutaneous biopsies.27 The anti-angiogenic effect of NB-UVB could be demonstrated by Chen, showing decreased levels of IL-8 and VEGF after therapy.28
Supported by a grant from the Health Research Board of Ireland.
Conflicts of interest: None identified.
Presented and published at the British Association of Dermatologists 2003 Annual Meeting in Brighton, United Kingdom [Presented July 1, 2003; published Br J Dermatol 2003;149(suppl):20] and American College of Rheumatologists 2003 Annual Meeting in Orlando, Florida [Presented October 23, 2003; published Arthritis Rheum 2003;48(Suppl):s168].